AngioDynamics, Inc. (UG2.F)
| Previous Close | 5.70 |
| Open | 5.75 |
| Bid | 5.80 x 25800 |
| Ask | 6.00 x 24800 |
| Day's Range | 5.75 - 5.80 |
| 52 Week Range | 4.76 - 10.20 |
| Volume | |
| Avg. Volume | 30 |
| Market Cap | 236.117M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
LATHAM, N.Y., April 04, 2024--AngioDynamics, Inc. (NASDAQ: ANGO):
- Business Wire
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE
LATHAM, N.Y., April 04, 2024--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that the United States Food and Drug Administration (FDA) has cleared the AlphaVac F1885 System for the treatment of pulmonary embolism (PE), enhancing its utility in critical medical scenarios such as PE.
- Business Wire
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.
LATHAM, N.Y., April 01, 2024--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company ("BD") to resolve all outstanding patent litigation with C.R. Bard, Inc., an affiliate of BD.
